Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
AUTOR(ES)
Bonecker, Simone, Magnago, Marina, Kaeda, Jaspal, Solza, Cristiana, Renault, Ilana Zalcberg
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2015-04
RESUMO
Documentos Relacionados
- Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
- Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
- Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
- Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil
- Molecular monitoring of BCR-ABL transcripts in patients with chronic myeloid leukemia treated with imatinib using real-time PCR